Charles River Laboratories (CRL) Tops Q2 EPS by 16c; Raises Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $187.51 -0.29%
Revenue Growth %: -5.1%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: -5.1%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.62, $0.16 better than the analyst estimate of $1.46. Revenue for the quarter came in at $585.3 million versus the consensus estimate of $571.33 million.
GUIDANCE:
Charles River Laboratories sees FY2018 EPS of $5.85-$6.00, versus prior of $5.77-$5.92 and the consensus of $5.84. Sees revenue growth of 19-21% versus 18-20%.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SailPoint Technologies Holdings (SAIL) Tops Q2 EPS by 1c, Offers Guidance
- McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
